Indefinite Delivery Contract HHSN261201600020I

The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer...

This federal contract IDV award by the National Cancer Institute (NCI), a civilian agency, provides for research and development services to support preclinical pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients. The prime contractor is the University of Pittsburgh - Of The Commonwealth System of Higher Education, a major public research university with extensive experience conducting federal research contracts and grants across biomedical sciences. The...

The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies. Under this...

The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...

The University of Texas MD Anderson Cancer Center was awarded an indefinite delivery, indefinite quantity (IDIQ) contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support the PREVENT Preclinical Drug Development Program. This multiple award IDIQ has a $74,995,000 ceiling and a 5-year base period with a 5-year option. It covers three pools of services: preclinical efficacy and biomarker evaluation, preclinical GMP product development and...

The key products and services being delivered under this federal contract IDV award from the National Cancer Institute (NCI) are preclinical toxicology studies on small molecule drug candidates for cancer and other indications. The prime contractor, IIT Research Institute (IITRI), a division of the Illinois Institute of Technology, will conduct non-GLP and GLP toxicology assessments in mice and dogs to support Investigational New Drug (IND) applications. IITRI holds several significant IDIQ...

The National Cancer Institute (NCI), part of the Department of Health and Human Services, has awarded an Indefinite Delivery Contract (IDC) valued at $29,800,000 to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The contract, titled "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS," has a period of performance from September 22, 2015 to September 21, 2018. Under this multiple-award IDC, The Institute for...

This federal indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the non-profit IIT Research Institute (IITRI). The $19 million PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) IDIQ contract vehicle enables NCI to efficiently access IITRI's preclinical research capabilities on an as-needed basis to support the development of cancer prevention therapies. Task orders issued under this...

This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...

The National Center for Advancing Translational Sciences (NCATS), a civilian agency, has awarded an indefinite delivery contract (IDC) worth up to $48,622,546 to Charles River Laboratories, Inc. to provide safety evaluation and toxicology studies and related services to support drug development. The contract has a period of performance from August 2024 to August 2030. Under this IDC, Charles River will perform in vitro and in vivo exploratory and Investigational New Drug (IND)-directed...